Cutting Edge: A2B Adenosine receptor signaling provides potent protection during intestinal ischemia/reperfusion injury.

Department of Anesthesiology and Intensive Care Medicine, Center for Inflammation and Hypoxia, University of Tübingen, Germany.
The Journal of Immunology (Impact Factor: 5.36). 05/2009; 182(7):3965-8. DOI: 10.4049/jimmunol.0802193
Source: PubMed

ABSTRACT Gastrointestinal ischemia/reperfusion (IR) injury significantly contributes to the morbidity and mortality of critical illness. In this study, we hypothesized a protective role for extracellular adenosine signaling in intestinal IR injury. Initial profiling studies of mucosal scrapings following murine IR demonstrated selective induction of the A2B adenosine receptor (A2BAR) transcript. Moreover, gene-targeted mice for the A2BAR showed more profound intestinal IR injury compared with controls. In contrast, A2AAR(-/-) mice exhibited no differences in intestinal injury compared with littermate controls. In addition, selective inhibition of the A2BAR resulted in enhanced intestinal inflammation and injury during IR. Furthermore, A2BAR agonist treatment (BAY 60-6583) protected from intestinal injury, inflammation, and permeability dysfunction in wild-type mice, whereas the therapeutic effects of BAY 60-6583 were abolished following targeted A2BAR gene deletion. Taken together, these studies demonstrate the A2BAR as a novel therapeutic target for protection during gastrointestinal IR injury.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nucleotides and nucleosides - such as adenosine triphosphate (ATP) and adenosine - are famous for their intracellular roles as building blocks for the genetic code or cellular energy currencies. In contrast, their function in the extracellular space is different. Here, they are primarily known as signaling molecules via activation of purinergic receptors, classified as P1 receptors for adenosine, or P2 receptors for ATP. Due to the fact that extracellular ATP is rapidly converted to adenosine by ectonucleotidase, nucleotide-phosphohydrolysis is important for controlling the balance between P2 and P1 signaling. Gene-targeted mice for P1, P2 receptors or ectonucleotidase exhibit only very mild phenotypic manifestations at baseline. However, they demonstrate alterations in disease susceptibilities when exposed to a variety of vascular or blood diseases. Examples for phenotypic manifestations include vascular barrier dysfunction, graft-versus-host disease, platelet activation, ischemia and reperfusion injury or sickle cell disease. Many of these studies highlight that purinergic signaling events can be targeted therapeutically.
    Blood 07/2014; 124(7). DOI:10.1182/blood-2013-09-402560 · 9.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Intestinal barrier dysfunction occurs in critical illnesses and involves the inflammatory and hypoxic injury of intestinal epithelial cells. Researchers are still defining the underlying mechanisms and evaluating therapeutic strategies for restoring intestinal barrier function. The anti‑inflammatory drug, emodin, has been shown to exert a protective effect on intestinal barrier function; however, its mechanisms of action remain unknown. In this study, we investigated the protective effects of emodin on intestinal barrier function and the underlying mechanisms in intestinal epithelial cells challenged with lipopolysaccharide (LPS) and hypoxia/reoxygenation (HR). To induce barrier dysfunction, Caco‑2 monolayers were subjected to HR with or without LPS treatment. Transepithelial electrical resistance and paracellular permeability were measured to evaluate barrier function. The expression of the tight junction (TJ) proteins, zonula occludens (ZO)‑1, occludin, and claudin‑1, as well as that of hypoxia‑inducible factor (HIF)‑1α, phospho‑IκB‑α, phospho‑nuclear factor (NF)‑κB p65 and cyclooxygenase (COX)‑2 was determined by western blot analysis. The results revealed that emodin markedly attenuated the decrease in transepithelial electrical resistance and the increase in paracellular permeability in the Caco‑2 monolayers treated with LPS and subjected to HR. Emodin also markedly alleviated the damage caused by LPS and HR (manifested by a decrease in the expression of the TJ protein, ZO‑1), and inhibited the expression of HIF‑1α, IκB‑α, NF‑κB and COX‑2 in a dose‑dependent manner. In conclusion, our data suggest that emodin attenuates LPS- and HR‑induced intestinal epithelial barrier dysfunction by inhibiting the HIF‑1α and NF‑κB signaling pathways and preventing the damage caused to the TJ barrier (shown by the decrease in the expression of ZO‑1).
    International Journal of Molecular Medicine 10/2014; 34(6). DOI:10.3892/ijmm.2014.1965 · 1.88 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The ectonucleotidases CD39 and CD73 sequentially degrade the extracellular ATP pool and release immunosuppressive adenosine, thereby regulating inflammatory responses. This control is likely to be critical in the gastrointestinal tract where high levels of ATP are released in particular by commensal bacteria. The aim of this study was therefore to evaluate the involvement of the adenosinergic regulation in the intestine of mice in steady-state conditions and on acute infection with Toxoplasma gondii. We show that both conventional (Tconv) and regulatory (Treg) CD4(+) T lymphocytes express CD39 and CD73 in the intestine of naive mice. CD73 expression was downregulated during acute infection with T. gondii, leading to impaired capacity to produce adenosine. Interestingly, the expression of adenosine receptors was maintained and treatment with receptor agonists limited immunopathology and dysbiosis, suggesting that the activation of adenosine receptors may constitute an efficient approach to control intestinal inflammation associated with decreased ectonucleotidase expression.Mucosal Immunology advance online publication, 12 November 2014; doi:10.1038/mi.2014.108.
    Mucosal Immunology 11/2014; DOI:10.1038/mi.2014.108 · 7.54 Impact Factor

Full-text (2 Sources)

Available from
Oct 1, 2014